Open Monoclonal Technology, Inc. Grants Unlimited OmniRat, OmniMouse And OmniFlic License
PALO ALTO, Calif.--(BUSINESS WIRE)--Open Monoclonal Technology, Inc. (OMT), an innovator of novel genetic engineering of animals for creation of human therapeutic antibodies, today announced an alliance with Genmab A/S (OMX: GEN), a biotechnology company specializing in human antibody therapeutics. The deal gives Genmab unlimited access to OMT’s three OmniAb™ platforms, OmniRat®, OmniMouse® and OmniFlic™.
Dr. Roland Buelow, founder and CEO of OMT, commented, “Genmab is a pioneer in the use of transgenic mice to develop therapeutic antibodies. OMT’s next generation transgenic animals will help Genmab create human antibody specificities for its DuoBody®, HexaBody™ and other new technologies and thus aid in creating therapeutic antibodies with superior efficacy.”
Help employers find you! Check out all the jobs and post your resume.
Dr. Roland Buelow, founder and CEO of OMT, commented, “Genmab is a pioneer in the use of transgenic mice to develop therapeutic antibodies. OMT’s next generation transgenic animals will help Genmab create human antibody specificities for its DuoBody®, HexaBody™ and other new technologies and thus aid in creating therapeutic antibodies with superior efficacy.”
Help employers find you! Check out all the jobs and post your resume.